WIPO Asian Regional Symposium on the Importance of the Intellectual Property System for High-Tech Industries

Guangzhou, China July 10 to 12, 2002

Case Studies

Successful Use of the Intellectual Property System; Turning High-Tech Inventions and Innovations into Profit-making Assets in the Marketplace

Karl Rackette

Freiburg, Germany info@rackette.de

Tuesday June 11, 12:25 pm Eastern Time Reuters Company News

Boston Scientific says wins German patent dispute

NATICK, Mass., June 11 (Reuters) -

Boston Scientific Corp. on Tuesday said a German court has ruled in its favor in a patent dispute with Medtronic Inc.

- SOURCE: Boston Scientific Corporation
- Boston Scientific Wins Infringement Case in Germany on Medtronic's Rapid Exchange Stent Delivery Systems and Angioplasty Balloons

- NATICK, Mass., June 11
- Boston Scientific Corporation announced today that a German Court has ruled that certain Medtronic AVE, Inc. rapid exchange stent delivery systems and angioplasty dilatation balloons infringe a patent licensed exclusively to Boston Scientific under the doctrine of equivalence.

- The Court's decision was announced orally today.
- A written decision is expected in several weeks.
- As is customary in such cases in Germany, the decision gives Boston Scientific the right to obtain an injunction against continued sales of Medtronic's infringing products in Germany, as well as damages.
- The decision will be subject to appeal by Medtronic.

The German patent involved in the case was granted to Dr. Tassilo Bonzel, and is a counterpart of the U.S. patent that an arbitration panel last year ruled had been willfully infringed by Medtronic.


In that proceeding, the panel awarded Boston Scientific \$169 million in damages, as well as costs and attorneys' fees, and a permanent injunction. The arbitrators' decision has been confirmed by a U.S. District Court, but Medtronic has appealed the decision.

Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices.

The Company's products are used in a broad range of interventional medical specialties.

United States Patent [19]		[11] Patent Number: 4,762,129			
Bonzel		[45]	Date of	Patent:	Aug. 9, 1988
[54] DILATATION CATHETER					
[76] Inventor: Tassilo Bonzel, N D-7800 Freiburg, Germany	eumattenstrasse 27, Fed. Rep. of	4,413, 4,439, 4,545,	989 11/1983 186 3/1984 390 10/1985	Schjeldahl et Kuhl Leary	al
[21] Appl. No.: 893,558			000 4/1986 648 10/1986		128/345 128/303 R
[22] PCT Filed: Nov. 15, 19	85				128/303.1
[86] PCT No.: PCT/DE85		FOREIGN PATENT DOCUMENTS			
§ 371 Date: Jul. 14, 198				Fed. Rep. of Fed. Rep. of	
§ 102(e) Date: Jul. 14, 198	6	2018	282 11/1080	Germany Fed. Rep. of	
[87] PCT Pub. No.: WO86/0312	29			Fed. Rep. of	
PCT Pub. Date: Jun. 5, 1980	5	329 1566		France . United Kingd	own.
[30] Foreign Application Prior	rity Data			United Kingd	
Nov. 23, 1984 [DE] Fed. Rep. of G		Primary B	raminer_I	Dalton L. Tre	lnek
[51] Int. Cl. ⁴		Primary Examiner—Dalton L. Truluck Assistant Examiner—Frank Wilkens Attorney, Agent, or Firm—Charles J. Knuth; Peter C. Richardson; Lawrence C. Akers			
		[57]		ABSTRACT	
[56] References Cited U.S. PATENT DOCUMENTS		A dilatation catheter, in particular for expanding constrictions in coronary vessels, includes a balloon (2) capable of being enlarged by injecting a fluid through a			
1,060,665 5/1913 Bell		tube (3). The tube (3) is arranged laterally offset from a segment of flexible tubing (7) by which a passage (8) for a guide wire (1) is formed in the balloon (2). 7 Claims, 1 Drawing Sheet			
3,882,852 5/1975 Sinnreich 4,198,981 4/1980 Sinnreich					

US Patent 4,762,129 claiming German Priority of Nov. 23, 1984



FACTUAL BACKGROUND

- In 1984, Bonzel invented a rapid exchange catheter known as the "monorail" catheter, now widely used for angioplasty procedures during cardiovascular surgery.
- He obtained patents for his invention in both Germany and the United States.

- In 1986, Bonzel licensed his invention to Schneider Medintag AG, a Swiss corporation which later changed its name to Schneider AG.
- Under the license, Bonzel transferred various exclusive rights in the patent in exchange for payments.
- Specifically, he transferred the right to sue for infringement of the patent.
- This license has been amended several times.
 The latest version is known as "Agreement (V)".

- Schneider AG shared the license with its sister company, Schneider (U.S.A.), based in Minnesota.
 Both Schneider AG and Schneider (U.S.A.) are controlled by Pfizer, Inc. ("Pfizer").
- In 1997, Pfizer dissolved Schneider AG, created Schneider GmbH, and moved Agreement(V) to the new company.
- In March 1998, Bonzel began receiving royalty payments from Switzerland from Schneider GmbH instead of Schneider AG.

- Pfizer has exercised its right to file suit in the United States against infringers of the Bonzel patent on several occasions.
- Patent infringement suits have been brought against Scientific and Life.
- From 1994 to 1998, Pfizer and Scientific were locked in three patent-related lawsuits through their subsidiaries, one filed by Scientific in Massachusetts, another filed by Pfizer in Minneapolis, and
- a third filed by Life in Germany ("the German litigation") concerning the validity of Bonzel's German patent.

- In September 1998, Scientific purchased the "Schneider Worldwide" division of Pfizer, which included Schneider GmbH and Schneider (U.S.A.).
- Schneider (U.S.A.) was subsequently renamed Boston Scientific Scimed, Inc.
- In the latter half of 1999, Scientific commenced paying royalty payments to Bonzel pursuant to Agreement (V) from Natick, Massachusetts.

Pfizer 2000 Annual Report

- Schneider Catheter Litigation
- On July 28, 2000, Dr. Tassilo Bonzel filed a suit against the Company and various currently or formerly affiliated codefendants in Minnesota state court alleging breach of contract, fraudulent transfer of his license agreement with Schneider (Europe) AG, unjust enrichment, breach of fiduciary duty, tortious interference with contractual relationship, and civil conspiracy, and seeking a declaratory judgment that Dr. Bonzel is free to terminate the aforementioned license agreement.

Pfizer 2000 Annual Report

 The claims arise from the Company's 1998 sale of the Schneider companies to Boston Scientific Corporation (BSC), which is named in Dr. Bonzel's complaint as an involuntary plaintiff.

BOSTON SCIENTIFIC CORP Annual Report

 On July 28, 2000, Dr. Tassilo Bonzel filed a complaint naming certain of the Company's Schneider Worldwide subsidiaries and Pfizer Inc. (Pfizer) and certain of its affiliates as defendants, alleging that Pfizer failed to pay Dr. Bonzel amounts owed under a license agreement involving Dr. Bonzel's patented Monorail(TM) technology. The suit was filed in the District Court for the State of Minnesota seeking monetary relief.

BOSTON SCIENTIFIC CORP Annual Report

- On September 26, 2001, Dr. Bonzel and the Company reached a contingent settlement involving all but one claim asserted in the complaint.
- Pursuant to the settlement agreement, the Company would acquire the Monorail technology and pay Dr. Bonzel approximately \$80 million contingent upon the occurrence of certain events.

Case Studies at www.wipo.int/sme/en/case_studies/index.htm

The table below is a compilation of concrete experiences of companies that have used the intellectual property system to improve their

comnetitiveness

MNATITIVANASS Title	Company	Subject Matter
Making Money from Royalties	Bishop Steering	Patents; Licensing; Managing IP
Living off the Intangible	Cash Engineering	Patents; Licensing
Using IP to attract Investors- the EAT-SET Project	EAT-SET	Patents; Financing
Australian invention dazzles Hollywood	Jim Frazier	Patents; Trade Secrets; Licensing
A Lesson Learned	Kambrook	Patents
Engineering Company Reaps Rewards by Smart IP Management	L&R Ashbolt	Patents; Managing IP; Patent Information
From Innovation to Commercialization and Beyond	Mandy Haberman	Patents; Licensing; Enforcement
Enforcing Intellectual Property Rights	Memtec	Patents; Enforcement
Queensland Tourist & Travel Corporation Stands by Their Trade Marks	Queensland Tourist & Travel	Trademarks; Marketing
An Impressive IP Strategy Model	The Dome Group	Managing IP
Innovation with Focus	The Mug Factory™	Trademarks; Licensing; Managing IP
Trouble in Paradise. Solved	Ztaag	Patents

THE END Thank you for your attention!

